Editas Medicine Inc (EDIT) concluded trading on Wednesday at a closing price of $11.07, with 7.17 million shares of worth about $79.35 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 22.73% during that period and on on Wednesday the price saw a gain of about 24.94%. Currently the company’s common shares owned by public are about 81.67M shares, out of which, 81.05M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 19 times over the past 12 months. They bought 239,267 shares in 6 of the transactions. In 13 selling transactions, insiders dumped 14,725 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the stock later moved at a day high price of 11.58, or with a gain of 24.94%. Stock saw a price change of 38.20% in past 5 days and over the past one month there was a price change of 45.09%. Year-to-date (YTD), EDIT shares are showing a performance of 9.28% which increased to 22.46% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.08 but also hit the highest price of $11.91 during that period. The average intraday trading volume for Editas Medicine Inc shares is 1.78 million. The stock is currently trading 44.59% above its 20-day simple moving average (SMA20), while that difference is up 27.36% for SMA50 and it goes to 27.51% higher than SMA200.
Editas Medicine Inc (NASDAQ: EDIT) currently have 81.67M outstanding shares and institutions hold larger chunk of about 73.36% of that.
The stock has a current market capitalization of $904.09M and its 3Y-monthly beta is at 2.01. It has posted earnings per share of -$2.71 in the same period. It has Quick Ratio of 6.12 while making debt-to-equity ratio of 0.10. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EDIT, volatility over the week remained 9.14% while standing at 6.08% over the month.
Analysts are in expectations that Editas Medicine Inc (EDIT) stock would likely to be making an EPS of -$0.54 in the current quarter, while forecast for next quarter EPS is -$0.6 and it is -$2.35 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.75 which is $0.21 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.88 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -24.44% while it is estimated to decrease by -9.76% in next year. EPS is likely to grow at an annualized rate of 1.70% for next 5-years, compared to annual growth of -1.50% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citigroup on October 24, 2023 offering a Buy rating for the stock and assigned a target price of $11 to it. Coverage by JP Morgan stated Editas Medicine Inc (EDIT) stock as a Neutral in their note to investors on October 18, 2023, suggesting a price target of $8 for the stock. On October 17, 2023, Cantor Fitzgerald Downgrade their recommendations, while on September 29, 2023, Stifel Upgrade their ratings for the stock with a price target of $17. Stock get an Outperform rating from Raymond James on June 12, 2023.
